Gabriel Morris
Director of Finance/CFO bei IMMIX BIOPHARMA, INC.
Vermögen: 991 054 $ am 31.03.2024
Aktive Positionen von Gabriel Morris
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
IMMIX BIOPHARMA, INC. | Director/Board Member | 01.03.2021 | - |
Director of Finance/CFO | 01.03.2021 | - | |
Investor Relations Contact | 01.03.2021 | - | |
Alwaysraise LLC | Corporate Officer/Principal | 01.01.2020 | - |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | President | - | - |
Karriereverlauf von Gabriel Morris
Ehemalige bekannte Positionen von Gabriel Morris
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Chief Operating Officer | - | 03.01.2021 |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Director of Finance/CFO | 01.01.2019 | 01.01.2020 |
Ausbildung von Gabriel Morris
The Trustees of Columbia University in The City of New York | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 7 |
Operativ
Director of Finance/CFO | 2 |
Director/Board Member | 1 |
Investor Relations Contact | 1 |
Sektoral
Health Technology | 3 |
Finance | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
IMMIX BIOPHARMA, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Campbell & Co. LP
Campbell & Co. LP Investment ManagersFinance Campbell & Co. LP provides investments management services. It is a pioneer in absolute return investment management, specializing in systematic managed futures and equity market-neutral strategies. The company provides absolute return investment strategies and global diversification in a single investment. Campbell & Co was founded in 1972 and is located in Towson, MD. | Finance |
ZAP Surgical Systems, Inc.
ZAP Surgical Systems, Inc. Internet Software/ServicesTechnology Services Zap Surgical Systems, Inc. operates as a gyroscopic radiosurgery platform. The company was founded by John R. Adler and is headquartered in San Carlos, CA. | Technology Services |
Alwaysraise LLC | |
Nexcella, Inc.
Nexcella, Inc. BiotechnologyHealth Technology Part of Immix Biopharma, Inc., Nexcella, Inc. is a clinical-stage biopharmaceutical company based in Los Angeles, CA. The private company is engaged in the discovery and development of novel cell therapies for oncology and other indications. Nexcella's lead candidate, next generation bcma-targeted car-t nxc-201, has produced high response rates in relapsed/refractory al amyloidosis and relapsed/refractory multiple myeloma, and has been awarded orphan drug designation by the FDA in both indications. The company's n-genius platform allows for the discovery, development, and manufacture of cutting-edge cell therapies for patients in need. Expansion into autoimmune indications is planned. | Health Technology |
- Börse
- Insiders
- Gabriel Morris
- Erfahrung